Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01876329 · ClinicalTrials.gov registry record
Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients
A clinical trial, sponsored by Keesler Air Force Base Medical Center.
- Completed
- Registry status
- 125
- Enrollment target
NCT01876329 is a clinical trial that has completed, run by Keesler Air Force Base Medical Center. The registered enrollment target is 125 participants.
The verdict
NCT01876329 has completed, sponsored by Keesler Air Force Base Medical Center.
- COMPLETED
- Registry status
- 125 participants
- Enrollment target
Study Summary
A review of the literature reveals that very few studies have assessed the potential co-existence of vitamin B12 deficiency due to gastric parietal cell autoantibodies. While Segal et al. in 2004 published a study which found that 49% of patients with RA had vitamin B12 deficiency, no assessment of the etiology or the presence of autoantibodies was made. While Goeldner et al. in 2011 and Datta et al. in 1990 demonstrated that anti-gastric parietal cell antibodies (anti-GPC Ab) were found in \<5% to 28% of RA patients respectively, no additional testing was implemented to determine the significance, specifically whether or not the presence of anti-GPC Ab related to vitamin B12 deficiency. The purpose of this study is to determine the prevalence and metabolic significance of anti-GPC Ab in three cohorts: (1) a group of patients with Rheumatoid Arthritis, (2) a group of patients with autoimmune thyroid disease (AITD), and (3) a group of patients with neither RA or AITD. To determine the significance of the presence of anti-GPC Ab, testing of the current serum B12 level along with a metabolite dependent on adequate vitamin B12 levels (Methylmalonic acid) will be tested.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01876329
The ClinicalTrials.gov registry entry for NCT01876329 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Keesler Air Force Base Medical Center, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01876329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01876329 about?
NCT01876329 is a clinical study titled "Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients". A review of the literature reveals that very few studies have assessed the potential co-existence of vitamin B12 deficiency due to gastric parietal cell autoantibodies. While Segal et al. in 2004 published a study which found that 49% of patients with RA had vitamin B12 deficiency, no assessment of ...
What is the current status of trial NCT01876329?
This trial is currently completed. The enrollment target is 125 participants. The study started on 2013-06. Estimated completion is 2015-04.
Who is sponsoring clinical trial NCT01876329?
This trial is sponsored by Keesler Air Force Base Medical Center, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.